Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$312 Mln
Revenue (TTM)
$228 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
10
P/B Ratio
2.4
Industry P/E
--
EV/EBITDA
4.6
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$2.5
EPS
$0.6
Face value
--
Shares outstanding
50,876,487
CFO
$-514.89 Mln
EBITDA
$-1,038.16 Mln
Net Profit
$-1,212.22 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| 16.0 | 21.1 | 16.0 | 135.5 | 30.7 | -7.1 | -13.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| 95.1 | -29.4 | 2.4 | 39.1 | -70.4 | 17.3 | -57.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
|
6.9 | 311.9 | 228.4 | 31.1 | 18.6 | 28 | 10 | 2.4 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat... adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 Read more
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
Headquarters
Los Angeles, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Puma Biotechnology Inc (PBYI) is $6.90 (NASDAQ) as of 02-Apr-2026 16:13 EDT. Puma Biotechnology Inc (PBYI) has given a return of 30.71% in the last 3 years.
The P/E ratio of Puma Biotechnology Inc (PBYI) is 10.05 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
9.85
|
2.35
|
|
2024
|
4.98
|
1.64
|
|
2023
|
9.63
|
3.89
|
|
2022
|
96,897.03
|
8.97
|
|
2021
|
-4.28
|
-51.01
|
The 52-week high and low of Puma Biotechnology Inc (PBYI) are Rs 7.68 and Rs 2.58 as of 03-Apr-2026.
Puma Biotechnology Inc (PBYI) has a market capitalisation of $ 312 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Puma Biotechnology Inc (PBYI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.